231 related articles for article (PubMed ID: 36769838)
1. Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer.
Tanczosova M; Hugo J; Gkalpakiotis S
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769838
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
3. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report.
Akhtar NH; Khosravi-Hafshejani T; Akhtar D; Dhadwal G; Kanani A
Allergy Asthma Clin Immunol; 2022 Feb; 18(1):9. PubMed ID: 35115035
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
6. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature.
Lobo Y; Lee RC; Spelman L
Case Rep Dermatol; 2021; 13(2):248-256. PubMed ID: 34177514
[TBL] [Abstract][Full Text] [Related]
7. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
[TBL] [Abstract][Full Text] [Related]
11. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
[TBL] [Abstract][Full Text] [Related]
13. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
[TBL] [Abstract][Full Text] [Related]
14. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
15. Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.
Mitroi GG; Stoica LE; Mitroi GF; Mitroi MR; Tutunaru CV; Ică OM; Ianoși LS
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295105
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report.
Giavina-Bianchi MH; Giavina-Bianchi P; Rizzo LV
Einstein (Sao Paulo); 2019 Jul; 17(4):eRC4599. PubMed ID: 31291386
[TBL] [Abstract][Full Text] [Related]
18. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults.
Xu X; Zheng Y; Zhang X; He Y; Li C
Oncotarget; 2017 Dec; 8(65):108480-108491. PubMed ID: 29312544
[TBL] [Abstract][Full Text] [Related]
20. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
